Drugs / NEXI-003 T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05582590 | Mar 2025 → Jul 2026 overdue | human papilloma virus infection, human papillomavirus-related squamous cell carcinoma, oropharynx squamous cell carcinoma | NexImmune Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NEXI-003 T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05582590 ↗ |
| Modality | Cell therapy | “Adoptive Cell Therapy specified dose on specified day(s)” NCT05582590 ↗ |
| Route | Intravenous | “administered by intravenous infusion on Day 1 of each cycle” NCT05582590 ↗ |